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Extensively drug resistant tuberculosis
A serious wake-up call for global health
Tuberculosis outbreaks in the developed worldare newsworthy.1 However, in the developingworld, where deaths from tuberculosis are
common, it takes something exceptional for an
outbreak to attract much attention. In response to a
recent report at the 16th international AIDS
conference2 and to increasing South African media
reports, the World Health Organization last week
expressed concern about extensively drug resistant
tuberculosis (also referred to as “XDR tuberculosis”).3
Among 536 culture confirmed cases of tuberculo-
sis at a rural hospital in South Africa, 41% were multi-
drug resistant,2 defined as resistance to rifampicin and
isoniazid (two key first line drugs). This is cause enough
for concern as multidrug resistant tuberculosis has a
worse outcome and its management is very difficult
even in high resource settings.4 Even more alarming
was that 53 (24%) of the isolates from multidrug resist-
ant tuberculosis fulfilled the definition of extensively
drug resistant tuberculosis2—namely, multidrug resist-
ant tuberculosis that is also resistant to at least three of
the six classes of second line agents. Such tuberculosis
is virtually untreatable.
All patients in this outbreak who were tested were
HIV infected, and 52 of the 53 died after a median of
just 25 days.2 In 90% of the isolates the same genetic
fingerprint was present, indicating extensive recent
transmission. Fifty six per cent of patients had
previously been admitted to hospital, raising the likeli-
hood of nosocomial transmission.
Outbreaks of infectious diseases are always more
newsworthy if their implications extend beyond the
local context, which is the case with extensively drug
resistant tuberculosis. For some years, such strains have
been known to exist in Asia, North and South America,
and Europe. In March this year, the Centers for Disease
Control and Prevention and WHO reported a survey
of over 17 000 tuberculosis isolates collected from
around the world between 2000 and 2004.5 Overall, 2%
of multidrug resistant strains were also extensively
drug resistant, being most frequently found in eastern
Europe, western Asia, and South Korea. Population
based data from the United States, Latvia, and South
Korea showed that 4%, 19%, and 15% respectively of
multidrug resistant strains could be defined as
extensively drug resistant.
The epidemiology and the limited genotypic data
currently available2 6 indicate that this is not a single
strain, but that extensively drug resistant strains are
likely to have emerged in many different places and on
multiple occasions. Paradoxically, this is both reassur-
ing and alarming. It is reassuring in that the emergence
of extensively drug resistant tuberculosis in more than
one strain suggests that the mutations responsible are
specific for drug resistance rather than reflecting a fun-
damental change in behaviour of the organism. This is
nevertheless alarming because it also suggests that
extensively drug resistant tuberculosis probably arises
fairly regularly and is already disseminated.
Drug resistance to tuberculosis results largely from
poorly managed care and control of the disease. Poor pre-
scribing practices, low drug quality (or erratic supply), and
suboptimal adherence can all contribute to this. Bacilli are
subject to intense drug selection, and exposure to mono-
therapy predisposes to an accumulation of mutations that
confer resistance. Hence optimal treatment includes four
drugs to which the organism is sensitive, and a single drug
should never be added to a failing regimen. In much of
the world, routine culture and sensitivity testing is not
available. Thus, where multidrug resistant tuberculosis
emerges, inappropriate treatment regimens may lead to
serial acquisition of resistance mutations, with potential
for emergence of extensively drug resistant tuberculosis.
Widespread use of second line tuberculosis drugs (such
as quinolones for respiratory tract infections) may also
contribute to the development of resistance. Thus, the
emergence of extensively drug resistant tuberculosis
should come as no surprise—it was entirely predictable in
the context of poor control practices.
The havoc that institutional transmission of multid-
rug resistant tuberculosis can wreak amongst HIV
infected people was evident in the US in the early
1990s.7 The very modest actual rise in the incidence of
tuberculosis that coincided with these outbreaks has
now been reversed,8 albeit with extraordinary effort and
cost. However, the huge potential for extensively drug
resistant tuberculosis to further undermine control
practices in communities in South Africa and elsewhere
in the region is self evident and would be much more
difficult to control. In some communities with an
antenatal prevalence of HIV of 30%, annual notification
rates for tuberculosis have already increased uncontrol-
lably over the past 10 years, reaching 1500/100 000—a
rate more than 250 times higher than rates in the US.9
Extensively drug resistant tuberculosis must now serve
as a serious wake-up call. Although the potential conse-
quences may be most grave in settings with a high
prevalence of tuberculosis and HIV, extensively drug
resistant tuberculosis is nevertheless already a very seri-
ous development in many other parts of the world too.5
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What response is needed? The global scale and
molecular epidemiology of extensively drug resistant
tuberculosis require urgent assessment, and laboratory
capacity needs to be greatly increased within a network
of sentinel sites. Control practices must be rigorously
and effectively implemented. Increasing cure rates for
tuberculosis through directly observed treatment short
course (DOTS) is crucial. Detection rates for cases of
tuberculosis need to be improved, highlighting the
need for a new diagnostic test. Technologies that can
determine the presence of drug resistance at the point
of care are needed, as are new drug treatments. The
DOTS-Plus strategy10 for treatment of multidrug resist-
ant tuberculosis needs to be further developed for
areas where the disease is established. Nosocomial
transmission of tuberculosis is probably commonplace
in the developing world, and simple, effective strategies
to reduce such transmission need to be urgently
implemented. More fundamentally, the emergence of
extensively drug resistant tuberculosis is a reminder
that tuberculosis needs massive broader commitment:
the incompletely funded Global Plan to Stop TB11
demands political will and financial action.
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Emergency contraception
Is it worth all the fuss?
Emergency contraception can prevent preg-nancy after unprotected sex, but it can also costyou your job. In 2005 an assistant commissioner
resigned from the Food and Drug Administration
(FDA) in the United States after a decision to make
emergency contraception available off prescription
was postponed indefinitely, despite two committees
recommending it (after three years’ delay the FDA has
recently approved over the counter sales, with
restrictions, of the emergency contraceptive Plan B).1
In 2006 two editors of the Canadian Medical Association
Journal (CMAJ) were fired, partly because they
published an article about access to emergency contra-
ception in Canadian pharmacies.2 Emergency contra-
ception has been described as “the latest battleground
in an ideologically divided America.”3 It has always
been a battleground, but is it worth all the fuss?
First used in the early 1970s, emergency contracep-
tion was a well kept secret until the late 1990s. At this
time interest in this form of contraception exploded
and considerable efforts were made to promote it.
Dedicated products are now available in many
countries, increasingly off prescription. Its use in most
countries is low, however. A minor proportion of
women undergoing abortion claim to have used emer-
gency contraception in the past to try to prevent preg-
nancy (1.3% in the US,4 2.9% in Sweden, and 9.2% in
France). In the United Kingdom its use has grown from
1% among women requesting an abortion in 1984, to
6% in 1996,5 and 12% in 2002.6
Emergency contraception has been heralded as the
solution to rising abortion rates. Some authors have
suggested that almost a million abortions could be pre-
vented in the US annually if every woman used
emergency contraception every time she needed it.7
Proponents claim that 43% of the reported fall in abor-
tions in the US (110 000 between 1994 and 2000) was
due to use of emergency contraception, and that around
51 000 pregnancies were prevented by its use in 2000-1.4
Similar calculations would lead us to conclude that
emergency contraception prevented more than 66 500
abortions in England andWales in 2004.
Yet, despite the clear increase in the use of
emergency contraception, abortion rates have not
fallen in the UK. They have risen from 11 per 1000
women aged 15-44 in 1984 (136 388 abortions) to 17.8
per 1000 in 2004 (185 400 abortions). Similarly,
increased use of emergency contraception in Sweden
has not been associated with a reduction in abortion
rates.8 A multitude of social and economic factors
influence pregnancy rates, and it is hard to show the
effect of a single factor. For example, the fall in the
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